Table 1 Baseline demographic, cognitive, and neuroimaging characteristics of study cohort
|
CN (n = 10) |
Prodromal AD (n = 26) |
Mild AD (n = 16) |
Moderate AD (n = 15) | p | |
|---|---|---|---|---|---|
| Demographics | |||||
| Age | 67.2 (6.2) | 69.8 (6.9) | 71.9 (4.9) | 70.8 (7.0) | 0.31 |
| Sex (% male) | 40% | 46% | 44% | 53% | 0.92 |
| Race/ethnicity (% non-Hispanic white) | 90% | 96% | 81% | 87% | 0.47 |
| APOE status (% ε4+) | 40% | 78% | 63% | 93%a | 0.023 |
| MMSE | |||||
| Baseline | 29.2 (0.8) | 28.0 (1.5) | 26.0 (2.9)a,b | 16.9 (2.8)a,b,c | <0.001 |
| % complete 18-month data | 90% | 85% | 75% | 73% | 0.65 |
| Average follow-up (days) | 509.8 (122.9) | 496.7 (128.9) | 520.4 (82.0) | 459.5 (141.9) | 0.55 |
| CDR-SB | |||||
| Baseline | 0.0 (0.2) | 1.6 (0.8)a | 3.3 (1.8)a,b | 6.4 (1.9)a,b,c | <0.001 |
| % complete 18-month data | 90% | 85% | 75% | 73% | 0.65 |
| Average follow-up (days) | 539.0 (124.3) | 535.0 (127.2) | 562.2 (76.6) | 482.7 (181.4) | 0.40 |
| ADAS-Cog13 | |||||
| Baseline | 9.3 (5.0) | 14.8 (5.5) | 22.1 (6.8)a,b | 40.3 (6.9)a,b,c | <0.001 |
| % complete 18-month data | 90% | 85% | 75% | 67% | 0.43 |
| Average follow-up (days) | 510.2 (123.1) | 497.2 (129.2) | 521.8 (83.4) | 447.4 (142.3) | 0.37 |
| RBANS Total Index | |||||
| Baseline | 93.0 (10.8) | 85.1 (11.8) | 73.2 (14.8)a,b | 55.8 (9.6)a,b,c | <0.001 |
| % complete 18-month data | 90% | 85% | 44%b | 27%b | <0.001 |
| Average follow-up (days) | 510.2 (123.1) | 497.2 (129.2) | 421.2 (165.7) | 361.2 (166.4)b | 0.031 |
| Neuroimaging | |||||
| [18F]GTP1: WCG SUVR | 1.12 (0.08) | 1.18 (0.09)a | 1.38 (0.26)a,b | 1.55 (0.40)a,b | <0.001 |
| [18F]florbetapir: cortical SUVR | 1.18 (0.18) | 1.37 (0.14)a | 1.38 (0.12)a | 1.41 (0.17)a | 0.003 |
| MRI: cortical volume (cm3) | 429.7 (39.4) | 444.5 (39.7) | 407.8 (31.0) | 372.4 (77.4)a,b | <0.001 |